Literature DB >> 9255158

D2-like dopamine receptor density in Tourette syndrome measured by PET.

D F Wong1, H S Singer, J Brandt, E Shaya, C Chen, J Brown, A W Kimball, A Gjedde, R F Dannals, H T Ravert, P D Wilson, H N Wagner.   

Abstract

UNLABELLED: Tourette syndrome (TS) is a chronic neurologic disorder characterized by the presence of involuntary motor and phonic tics. There is evidence that TS is associated with an abnormality of the dopaminergic system, involving postsynaptic D2 receptors. We tested the hypothesis that D2-like dopamine receptors are elevated in TS.
METHODS: Twenty-nine adult patients with TS were studied by PET imaging with [11C]3-N-methylspiperone ([11C]NMSP). Two methods of data analysis were used. The first was a caudate-to-cerebellar ratio, measured at 45 min. The second method, applied in 20 subjects, was a two-PET scan procedure. Both used high specific activity [11C]NMSP, but the second scan was preceded by a dose of unlabeled haloperidol, which partially occupied the D2-like dopamine receptors. This was done to provide an absolute measure of receptor density (Bmax). All patients were compared to age- and sex-matched controls.
RESULTS: Neither group showed significant differences from their control group in caudate-to-cerebellar ratio. However, the two-PET scan Bmax measurement demonstrated that 4 of the 20 patients had significantly elevated D2-like receptors. In this group of 20 patients, multiple linear regression analysis revealed a trend between the severity of vocal tics and Bmax values. This Bmax measure also revealed a significant (p < 0.05) association with performance on the Wisconsin Card Sorting Test.
CONCLUSION: These findings suggest that not all patients with TS have an abnormality of D2-like receptors, but a subgroup of TS subjects has a significant D2-like dopamine receptor elevation. These findings also support the importance of applying a more quantitative method for Bmax determination to PET imaging analysis. The Bmax findings in the subgroup do not exclude an effect of intrasynaptic dopamine competition, but this effect may be less likely due to the high affinity of [11C]NMSP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9255158

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.

Authors:  Paul R Sanberg; Cecilia Vindrola-Padros; R Douglas Shytle
Journal:  Physiol Behav       Date:  2012-07-06

2.  Chronic ACE inhibitor treatment increases angiotensin type 1 receptor binding in vivo in the dog kidney.

Authors:  Tamas G Zober; Maria Elena Fabucci; Wei Zheng; Phillip R Brown; Esen Seckin; William B Mathews; Kathryn Sandberg; Zsolt Szabo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

Review 3.  A Review and Update on Tourette Syndrome: Where Is the Field Headed?

Authors:  Aysegul Gunduz; Michael S Okun
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

4.  Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.

Authors:  Elia Abi-Jaoude; Barbara Segura; Ignacio Obeso; Sang Soo Cho; Sylvain Houle; Anthony E Lang; Pablo Rusjan; Paul Sandor; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2015-03-18       Impact factor: 5.038

5.  Pharmacologic MRI (phMRI) as a tool to differentiate Parkinson's disease-related from age-related changes in basal ganglia function.

Authors:  Anders H Andersen; Peter A Hardy; Eric Forman; Greg A Gerhardt; Don M Gash; Richard C Grondin; Zhiming Zhang
Journal:  Neurobiol Aging       Date:  2014-10-16       Impact factor: 4.673

6.  Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Authors:  Dean F Wong; James R Brasić; Harvey S Singer; David J Schretlen; Hiroto Kuwabara; Yun Zhou; Ayon Nandi; Marika A Maris; Mohab Alexander; Weiguo Ye; Olivier Rousset; Anil Kumar; Zsolt Szabo; Albert Gjedde; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2007-11-07       Impact factor: 7.853

Review 7.  Functional disturbances within frontostriatal circuits across multiple childhood psychopathologies.

Authors:  Rachel Marsh; Tiago V Maia; Bradley S Peterson
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

8.  Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates.

Authors:  Jo Ann V Antenor-Dorsey; Richard Laforest; Stephen M Moerlein; Tom O Videen; Joel S Perlmutter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12-11       Impact factor: 9.236

Review 9.  The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.

Authors:  Cathy L Budman
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 10.  Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation.

Authors:  Bahar Salavati; Tarek K Rajji; Rae Price; Yinming Sun; Ariel Graff-Guerrero; Zafiris J Daskalakis
Journal:  Schizophr Bull       Date:  2014-09-22       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.